Can Polyamines act as Positron Emitters in Cerebral Oncology? Preliminary results obtained in nude mice bearing human glioblastoma xenografts

  • V. Quemener
  • F. Darcel
  • M. Chatel
  • J.-Ph. Moulinoux
Part of the Developments in Oncology book series (DION, volume 52)


The polyamines, such as putrescine (PUT), spermidine (SPD) and spermine (SPM) are saturated organic compounds which are present in abnormally high concentration in malignant brain tumours (1, 2,3). In addition, the levels of PUT and SPD in the tumour are, statistically speaking, proportional to the histological grade of the tumour (2, 4). Furthermore, Marton et al. (5, 6) demonstrated that the presence of a brain tumour was associated with a significant increase in the concentration of PUT in the CSF; this type of analysis has been found to be very useful in the management of medulloblastoma (7, 8). In a similar vein, we have observed that the levels of SPD and SPM measured in the red blood cells were significantly elevated in patients afflicted with malignant supratentorial tumours (4). The determination of RBC polyamine levels now appears to have clinical applications, not only for monitoring (9, 10) but also during the post-operative treatment of patients with malignant gliomas (11).

Key words

Polyamines Gliomas Positron Nude mice Xenografts 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harik (S.J.) et al.: Putrescine as a biochemical marker for malignant brain tumors. Neurology. 28, 351 (1978).Google Scholar
  2. 2.
    Harik (S.I.) et al.: Putrescine as biochemical marker of malignant brain tumors, Cancer Res., 39, 5010–5015 (1979).PubMedGoogle Scholar
  3. 3.
    Kremzner (L.T.) et al.: Polyamine metabolism in the central and peripheral nervous system. Ann. N.Y. Acad. Sci., 171, 735–748 (1970).CrossRefGoogle Scholar
  4. 4.
    Moulinoux (J.PH.) et al.: Polyamines in human brain tumors: a correlative study between tumor, CSF and red blood cell free polyamine levels. J. Neuro-Oncology (JNO), 1984, 2, 153–158.Google Scholar
  5. 5.
    Marton (L.J.) et al.: Increased polyamine concentrations in the CSF of patients with brain tumors. Int. J. Cancer, 14, 731–735 (1974).PubMedCrossRefGoogle Scholar
  6. 6.
    Marton (L.J.) et al.: The relationship of the polyamines in the CSF to the presence of central nervous system tumors. Cancer Res., 36, 973–977 (1976).PubMedGoogle Scholar
  7. 7.
    Marton (L.J.) et al.: Predictive value of cerebrospinal fluid polyamines in medulloblastoma. Cancer Res., 39, 993–997 (1979).PubMedGoogle Scholar
  8. 8.
    Marton (L.J.) et al.: CSF polyamines: a view and important means of monitoring patients with medulloblastoma. Cancer, 47, 757–760 (1981).PubMedCrossRefGoogle Scholar
  9. 9.
    Moulinoux (J.PH.) et al.: Red blood cell polyamines in malignant glioma patients. Spermidine and spermine blood levels and tumour evolution. J.N. Oncol., in press (1986).Google Scholar
  10. 10.
    Chatel (M.) et al.: Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas, J. Anticancer Res., in press (1986).Google Scholar
  11. 11.
    Theron (J.) et al.: Intra-arterial chemotherapy with BCNU. Correlations between tumour growing and red blood cells polyamines levels. (Cf. present volume).Google Scholar
  12. 12.
    Volkow (N.) et al.: Labelled putrescine as a probe in brain tumors, Sciences, 221, 673–675 (1983).CrossRefGoogle Scholar
  13. 13.
    Goldman (S.S.) et al.: Putrescine metabolism in human brain tumors, J.N. Oncol., 4, 23–27 (1986).CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1987

Authors and Affiliations

  • V. Quemener
    • 1
  • F. Darcel
    • 2
  • M. Chatel
    • 2
  • J.-Ph. Moulinoux
    • 1
  1. 1.Groupe de Recherche en Therapeutique AnticancéreuseCHU de RennesRennesFrance
  2. 2.Laboratoire de Neuro-pathologieCHU de RennesRennesFrance

Personalised recommendations